logo
Products
Technologies
Applications
Services
Resources
Selection Guides
About
PE/iFluor® 594 Anti-human CD138 Antibody
MI15
The MI15 monoclonal antibody reacts with human CD138, a 100 - 200 kD transmembrane protein typically expressed on the surface of b cells, plasma cells, epithelial cells and endothelial cells. CD138 is involved with important cellular pathways, in particular, the cytokine-mediated signaling pathway and canonical Wnt signaling pathway. Also, in certain organisms, it enhances extracellular exosome assembly and is a promoter of exosomal secretion. From a research standpoint, it is of biological interest due to its association with critical macromolecules/ligands such as Fibronectin. CD138 is a fairly uncommon antibody target, with a little more than 7000 publications in the last decade. Even still, CD138 is frequently used in flow cytometry applications as a phenotypic marker for differentiation of cell types, specifically in the study of cell motility/cytoskeleton/structure, cell biology and synaptic biology. This antibody was purified through affinity chromatography and conjugated to PE/iFluor® 594 (ex/em = 566/606 nm). It is compatible with the 561 nm laser and 610/30 nm bandpass filter (for example, as in the Luminex Amnis FlowSight).
product image
product image
CatalogSize
Price
Quantity
113801Y025 tests
Price
113801Y1100 tests
Price
113801Y2500 tests
Price
 
Antibody properties

Other namesSyndecan-1
CloneMI15
Hostmouse
Isotypemouse IgG1
Reactivityhuman
Spectral properties

Absorbance (nm)566
Extinction coefficient (cm -1 M -1)
1960000
Excitation (nm)565
Emission (nm)606
Storage, safety and handling

H-phraseH303, H313, H333
Hazard symbolXN
Intended useResearch Use Only (RUO)
R-phraseR20, R21, R22
Contact us

Telephone
Fax
Emailsales@aatbio.com
InternationalSee distributors
Bulk requestInquire
Custom sizeInquire
Technical SupportContact us
Request quotationRequest
Purchase orderSend to sales@aatbio.com
ShippingStandard overnight for United States, inquire for international
Page updated on October 7, 2025